Genialis Unveils Expressions Version 3.0, Cloud Software for Faster, More Secure Data Processing and Management
Updated Microservices and Front End Architectures Deliver Vastly Improved [...]
The Xerna™ TME Panel potentially predicts response to a combination of the TLR9 agonist vidutolimod and PD-1 inhibitor pembrolizumab in metastatic melanomas with prior anti-PD-1 treatment
This poster illustrates the potential of the Xerna™ TME [...]
ResponderID™: The Biology-First Machine Learning Platform for Biomarker Discovery
Rarely has a complex gene signature been successfully translated [...]
Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response
Through AI/ML-enabled platform with a biology-first approach, Genialis looks [...]
Communication, the key to building community with Susanna Harris | Podcast #29
Welcome to Talking Precision Medicine — the podcast in [...]
Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience
Abstract: We describe our institutional experience of developing a [...]
A new way to finance drug development, for rare disease and beyond with Alok Tayi | Podcast #28
Welcome to Talking Precision Medicine — the podcast in [...]
Xerna tumor microenvironment subtypes as a biomarker in lung cancer patients
This study investigates the potential of the Xerna™ TME [...]
SITC 2022: some thoughts in review
By Luka Ausec and Daniel Pointing Below are some observations, [...]
Genialis Presents New Clinical Biomarker Findings at SITC, BioTechX
I/ML technology used to enhance drug development included in [...]
